Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
LB.1.4.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.64NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.19NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.29.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.24.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.18.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LU.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
MG.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.59NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LG.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LK.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LB.1.7.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.25 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.25.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.25.3 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.75 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.100 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.44 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.2.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LD.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KW.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KR.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.15.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.50.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LB.1.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
LF.3.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDP.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
KP.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.31NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.11.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JD.1.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.13.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.32.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.4.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.86.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.34NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JG.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used